ReNeuron

ReNeuron was a UK-based biotechnology company focused on the development of stem-cell therapies for diseases with substantial unmet medical needs. Its research program centered on the use of stem cells to repair or replace damaged tissue, with particular attention to neurological conditions, peripheral arterial disease, stroke, and retinal disorders. The company’s work formed part of the broader effort to translate regenerative-medicine research into clinical treatments. Rather than operating as a consumer-facing healthcare brand, ReNeuron functioned primarily as a research and development enterprise whose value depended on scientific progress, clinical evidence, regulatory development, and the potential commercialization of cell-based medicines. Its programs were directed at conditions in which conventional treatments could not adequately restore lost function or reverse tissue damage. By 2010, ReNeuron was reported to be investigating neural stem cells for spinal-cord regeneration and fetal stem-cell approaches for stroke patients. These activities reflected the company’s emphasis on regenerative applications in the central nervous system. The company also pursued programs involving peripheral arterial disease and retinal disease, extending its research beyond the brain and spinal cord into vascular and ophthalmic indications. ReNeuron’s corporate history was linked to the financial and operational challenges often faced by biotechnology companies developing advanced therapies. Its shares had been traded on London’s Alternative Investment Market, but the company entered administration and was delisted in August 2024. The available reference material does not establish the full circumstances of the administration, the disposition of its intellectual property, or whether any of its therapeutic programs continued under another owner. Accordingly, ReNeuron is best described as a former biotechnology company whose principal identity was its stem-cell research portfolio rather than a currently operating commercial pharmaceutical business.

ReNeuron developed as a UK biotechnology company dedicated to stem-cell research and regenerative medicine. Its scientific focus was on using cell-based approaches to address tissue damage and loss of function in diseases for which existing medical interventions were inadequate. The company’s work was therefore positioned within advanced therapeutics rather than conventional pharmaceutical development or medical-device manufacturing. The company investigated several therapeutic areas. Its portfolio included research relating to peripheral arterial disease, stroke, and retinal diseases, all of which can involve severe, persistent impairment and limited capacity for natural tissue repair. Neurological regeneration was a particularly important theme. By 2010, ReNeuron was testing neural stem-cell approaches in connection with spinal-cord regeneration and examining fetal stem-cell applications for stroke patients. These programs represented attempts to use transplanted cells to support repair or recovery in damaged nervous-system tissue. ReNeuron’s research model was characteristic of development-stage biotechnology companies: scientific programs were advanced through preclinical and clinical investigation, with future commercial prospects dependent on safety, efficacy, regulatory approval, manufacturing feasibility, and access to financing. The reference material does not provide enough information to establish the precise clinical stages, trial outcomes, product approvals, partnerships, or commercial revenues associated with each program, so those details are not stated here. The company’s shares were listed on London’s Alternative Investment Market. In August 2024, ReNeuron entered administration and was delisted from AIM. This ended its status as a publicly traded biotechnology company. The available source does not identify a successor operating company, a confirmed acquirer, or the final disposition of its research assets. ReNeuron’s documented legacy is therefore primarily its attempt to develop stem-cell therapies for neurological, vascular, and retinal conditions, together with its eventual failure as a listed corporate entity.

• 2024

  Administration and AIM delisting

  [1]ReNeuronen.wikipedia.org

  The company entered administration and was delisted from London’s Alternative Investment Market in August 2024.

• 2010

  Neural and fetal stem-cell research reported

  [1]ReNeuronen.wikipedia.org

  ReNeuron was reported to be investigating neural stem cells for spinal-cord regeneration and fetal stem-cell approaches for patients affected by stroke.

A specialist regenerative-medicine and biotechnology company focused on translating stem-cell research into therapies for serious diseases with limited treatment options.

• Regenerative medicine

  Neural stem-cell therapy programs

  ReNeuron’s neural stem-cell research was directed toward repairing or regenerating damaged nervous-system tissue. The documented applications included spinal-cord regeneration and other neurological conditions. The available reference does not establish an approved commercial product or provide sufficient detail about the final clinical status of these programs.

• Regenerative medicine

  Fetal stem-cell stroke research

  The company investigated the potential use of fetal stem cells in patients affected by stroke. This work formed part of ReNeuron’s broader effort to develop cell-based treatments for neurological damage, but the available source does not document an approved therapy or a commercial launch.

• Cell therapy

  Peripheral arterial disease programs

  ReNeuron identified peripheral arterial disease as one of the areas of unmet medical need addressed by its stem-cell development efforts. The supplied reference confirms the therapeutic focus but does not provide enough information to describe a named product, clinical outcome, or commercialization status.

• Cell therapy

  Retinal disease programs

  Retinal diseases were among the indications targeted by ReNeuron’s stem-cell research. The company’s aim was consistent with its wider regenerative-medicine strategy of addressing diseases involving tissue damage and limited natural recovery. No approved product or specific program name is established by the available material.

• 2024

  Entry into administration and withdrawal from public tradingOther

  Background

  ReNeuron was a publicly listed biotechnology company whose shares traded on AIM. The available reference records that it entered administration in 2024.

  Action taken

  The company entered administration and its AIM listing was cancelled in August 2024.

  Aftermath

  ReNeuron ceased to be a listed company. The available source does not establish whether its research programs or assets were transferred to another organization.

  Source

• 2020.04.07

  Reported2020.04.07

  ReNeuron announces exosome research collaboration[2]ReNeuron宣布外泌体研究合作prnewswire.com

  ReNeuron announced that it had signed a research agreement with an unnamed major pharmaceutical company to explore using ReNeuron's exosomes to deliver therapeutics. ReNeuron will manufacture and load the exosomes, which the pharmaceutical company will evaluate.

Read more

1. 1ReNeuronen.wikipedia.org
2. 2ReNeuron宣布外泌体研究合作prnewswire.com
3. 3ReNeuron Signs New Exosome Research Collaborationprnewswire.com